Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers

被引：6

作者：

Humeniuk, Michael S. ^{[1
]}

Zhang, Tian ^{[1
,2
]}

Armstrong, Andrew J. ^{[2
,3
,4
,5
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[2] Duke Canc Inst, Durham, NC USA

[3] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA

[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA

[5] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA

来源：

CANCER | 2017年 / 123卷 / 18期

关键词：

MEN; SURVIVAL;

D O I：

10.1002/cncr.30806

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The report in this issue by Pomerantz and colleagues demonstrates that men with metastatic prostate cancer harboring germline BRCA2 mutations are strongly associated with a prostate-specific antigen response 50% during treatment with a platinum agent. However, more work will be required to classify other men who might benefit from platinum agents. See also pages 3532-9.

引用

页码：3441 / 3444

页数：4

共 50 条

[41] BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy
Takada, Mamoru
Nagai, Shigenori
Haruta, Masayuki
Sugino, Ryuichi P.
Tozuka, Katsunori
Takei, Hiroyuki
Ohkubo, Fumie
Inoue, Kenichi
Kurosumi, Masafumi
Miyazaki, Masaru
Sato-Otsubo, Aiko
Sato, Yusuke
Ogawa, Seishi
Kaneko, Yasuhiko
GENES CHROMOSOMES & CANCER, 2017, 56 (05): : 405 - 420
[42] Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
Kristeleit, Rebecca S.
Oaknin, Ana
Ray-Coquard, Isabelle
Leary, Alexandra
Balmana, Judith
Drew, Yvette
Oza, Amit M.
Shapira-Frommer, Ronnie
Domchek, Susan M.
Cameron, Terri
Maloney, Lara
Goble, Sandra
Lorusso, Domenica
Ledermann, Jonathan A.
McNeish, Iain A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1396 - 1404
[43] Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer
Cheng, Heather H.
Salipante, Stephen J.
Nelson, Peter S.
Montgomery, Bruce
Pritchard, Colin C.
JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 5
[44] Platinum-based chemotherapy for metastatic insulinoma harboring germline mutation in DNA damage repair pathway: a case report
Yang Kaili
Ying Hongyan
Guan Mei
Wang Lina
Xu Jia
Cheng Yuejuan
胰腺病学杂志（英文）, 2024, 07 (02)
[45] Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Banerjee, S.
Imbimbo, M.
Roxburgh, P.
Kim, J-W.
Kim, M. H.
Plummer, R.
Stemmer, S.
You, B.
Ferguson, M.
Penson, R. T.
O'Malley, D.
Meyer, K.
Gao, H.
Angell, H.
Nunes, A. Tablante
Domchek, S.
Drew, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S788 - S789
[46] Platinum-based chemotherapy for metastatic insulinoma harboring germline mutation in DNA damage repair pathway: a case report
Yang, Kaili
Ying, Hongyan
Guan, Mei
Wang, Lina
Xu, Jia
Cheng, Yuejuan
JOURNAL OF PANCREATOLOGY, 2024, 7 (02) : 167 - 169
[47] Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy
Friedlander, M. L.
Hettle, R.
Parkhomenko, E.
ANNALS OF ONCOLOGY, 2019, 30
[48] PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.
Drewett, Lynsey
Lucey, Rebecca
Pinilla, Karen Andrea
Grybowicz, Louise
Wulff, Jerome
Dayimu, Alimu
Demiris, Nikos
Vallier, Anne-Laure
Qian, Wendi
Machin, Andrea
McAdam, Karen
Roylance, Rebecca
Copson, Ellen
Armstrong, Anne C.
Levitt, Nicola
Provenzano, Elena
Tischkowitz, Marc D.
McMurtry, Emma
Earl, Helena Margaret
Abraham, Jean
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Penson, Richard T.
Valencia, Ricardo Villalobos
Cibula, David
Colombo, Nicoletta
Leath, Charles A.
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo-Hyun
Madry, Radoslaw
Hernandez, Carlos Hernandez
Mora, Paulo Alexandre Ribeiro
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review
Armstrong, Nigel
Quek, Ruben G. W.
Ryder, Steve
Ross, Janine
Forbes, Carol
Fox, Kathleen M.
Castro, Elena
FUTURE ONCOLOGY, 2021, 17 (07) : 853 - 864

← 1 2 3 4 5 →